Effective removal of methotrexate by high-flux hemodialysis. 2002

Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
Department of Pediatrics, The Mount Sinai School of Medicine, One Gustave L. Levy Place Box 1664, NY 10029-6574, USA.

The purpose of the present study was to examine the clearance of methotrexate (MTX) by high-flux hemodialysis (HD) in pediatric oncology patients. We present three patients who experienced nephrotoxicity and prolonged exposure to toxic MTX concentrations following high-dose infusions during treatment for osteogenic sarcomas. Each patient was successfully treated with high-flux HD, followed by carboxypeptidase G2 (CPDG2) in two cases. Minimal systemic toxicity occurred. We review the literature and discuss guidelines for early and aggressive treatment for this complication of high-dose MTX therapy. Clinically important removal of MTX depends upon prompt initiation of HD after detection of nephrotoxicity and delayed clearance of MTX. Therapy is indicated in cases where compassionate use of CPDG(2) may not be available, or while awaiting its delivery.

UI MeSH Term Description Entries
D007008 Hypokalemia Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed) Hypopotassemia,Hypokalemias,Hypopotassemias
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D011623 gamma-Glutamyl Hydrolase Catalyzes the hydrolysis of pteroylpolyglutamic acids in gamma linkage to pterolylmonoglutamic acid and free glutamic acid. EC 3.4.19.9. Conjugase,Folate Conjugase,Folyl Conjugate Synthetase,Pteroyl Polyglutamate Hydrolase,Carboxypeptidase G,Carboxypeptidase G1,Carboxypeptidase G2,Folacin Conjugase,Folate Hydrolyzing Enzyme,Folyl Poly-gamma-Glutamate Carboxypeptidase,Folyl Polyglutamate Cleavage Enzyme,Folylpolyglutamate Hydrolase,gamma Glutamyl Hydrolase
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses

Related Publications

Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
December 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
July 1992, Antimicrobial agents and chemotherapy,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
January 2016, ASAIO journal (American Society for Artificial Internal Organs : 1992),
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
March 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
May 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
January 2013, Journal of nephrology,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
November 2001, Renal failure,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
December 2012, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
October 2000, The Annals of pharmacotherapy,
Jeffrey M Saland, and Patrick J Leavey, and Robert O Bash, and Eleonora Hansch, and Gerald S Arbus, and Raymond Quigley
January 2023, Blood purification,
Copied contents to your clipboard!